Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation

Lancet

Volumn 355, Issue 9220, 2000, Pages 2015-2020

  Meijers Heijboer, E J ^a   Verhoog, L C ^c   Brekelmans, C T M ^c   Seynaeve, C ^c   Tilanus Linthorst, M M A ^c   Wagner, A ^a   Dukel, L ^c   Devilee, P ^b   Van Den Ouweland, A M W ^a   Van Geel, A N ^c   Klijn, J G M ^c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CLINICAL TRIAL; DNA DETERMINATION; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MULTIVARIATE ANALYSIS; ONCOGENE; OVARIECTOMY; OVARY CANCER; PARENT; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0034631316     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02347-3     Document Type: Article

References (29)

1. Ford D., Easton D.F., Stratton M.et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
2. Easton D.F., Ford D., Bishop D.F. Breast and ovarian cancer incidence in BRCA1-mutations carriers. Am J Hum Genet. 56:1995;265-271.
3. Struewing J.P., Hartge P., Wacholder S.et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1997;1401-1408.
4. Ford D., Easton D.F., Bishop D.T.et al. Risks of cancer in BRCA1 mutation carriers. Lancet. 343:1994;992-995.
5. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 91:1999;1310-1316.
6. Easton D.F., Steele L., Fields P.et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 61:1998;120-128.
7. Breast Cancer Information Core (1999) http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic (accessed May 30, 2000).
8. Lerman C., Seay J., Balshem A., Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet. 57:1995;385-392.
9. Jacobsen P.B., Valdimarsdottir H.B., Brown K.L., Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med. 59:1997;459-466.
10. Lerman C., Narod S., Shulman K.et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 275:1996;1885-1892.
11. Lynch H.T., Lemon S.J., Durham C.et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228.
12. Lynch H.T., Watson P., Tinley S.et al. An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet. 109:1999;91-98.
13. Verhoog L.C., Brekelmans C.T.M., Seynaeve C.et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:1998;316-321.
14. Verhoog L.C., Brekelmans C.T.M., Seynaeve C.et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 17:1999;3396-3402.
15. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol. 14:1996;1730-1736.
16. Klijn J.G.M., Janin N., Cortes-Funes H., Colomer R. Should prophylactic surgery be used in women at high risk of breast cancer? Eur J Cancer. 33:1997;2149-2159.
17. Miki Y., Swensen J., Shattuck-Eidens D.et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
18. Wooster R., Bignell G., Lancaster J.et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 378:1995;789-792.
19. Shrag D., Kuntz K.M., Garber J.E.et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 336:1997;1465-1471.
20. Eisinger F., Geller G., Burke W., Holtzman N.A. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet. 353:1999;919-920.
21. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst. 90:1998;1371-1388.
22. Powles T., Eeles R., Ashley S.et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
23. Eisen A., Weber B.L. Prophylactic mastectomy - the price of fear. N Engl J Med. 340:1999;137-138.
24. Hartmann L.C., Schaid D.J., Woods J.E.et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 340:1999;77-84.
25. Rosenthal A., Jacobs I. Ovarian Cancer Screening. Semin Oncol. 25:1998;315-325.
26. Piver M.S., Jishi M.F., Tsukada Y.et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. a report of the Gilda Radner Familial Ovarian Cancer Registry Cancer. 71:1993;2751-2755.
27. Stefanek M.E., Helzlsouer K.J., Wilcox P.M., Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 24:1995;412-419.
28. Borgen P.I., Hill A.D., Tran K.N.et al. Patients regrets after bilateral prophylactic mastectomy. Ann Surg Oncol. 7:1998;603-606.
29. Lerman C., Hughes C., Lemon S.J.et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol. 16:1998;650-1654.